Structure-based vaccines that graft conformational epitopes of alpha-synuclein (α-syn) amyloid fibrils onto the fungal HET-s(218-298) prion-domain scaffold elicited IgG antibodies selective for pathological fibrils (Flores-Fernandez et al., 2024), and the efficacy question that work left open — whether vaccination alters disease progression — has since been answered affirmatively in prophylactic TgM83+/- mouse challenge models, where vaccination prolonged median survival by up to 42%, delayed weight loss and motor decline, and delayed Parkinson-like neuropathology (Pesch et al., Brain 2024; Ma et al., Brain 2026). The surviving open problem is whether this vaccine class can become a clinically viable intervention: whether the elicited antibodies avoid harmful autoimmune reactions, disruption of physiological α-syn function, and adverse neuroinflammation in vivo; how long antibody titers and protection persist and whether booster regimens can sustain them; whether protection extends across diverse patient-derived α-syn strains rather than a single synthetic fibril preparation; whether vaccination works therapeutically after pathology has begun rather than only prophylactically; and whether mouse immunogenicity, safety, and efficacy translate to humans, for whom no trial of this vaccine class has been registered.

Background

Synucleinopathies — Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) — are progressive neurodegenerative disorders driven by the misfolding and aggregation of alpha-synuclein (α-syn), a normally soluble neuronal protein, into toxic oligomers and insoluble amyloid fibrils that deposit as Lewy bodies and glial cytoplasmic inclusions. Pathological α-syn aggregates behave prion-like: they spread between neurons and seed further aggregation of monomeric α-syn. Distinct fibril conformations ('strains') are associated with different diseases, and cryo-electron microscopy has resolved the atomic structures of both synthetic and ex vivo patient-derived α-syn fibrils. Active immunotherapy against α-syn has so far failed clinically: earlier vaccines used short linear peptides without control of antigen structure, so the immune system could not reliably distinguish native monomeric α-syn from the amyloid form, and trials (e.g., the AFFITOPE PD01A/PD03A program) did not demonstrate disease modification. A key readout platform is the hemizygous TgM83+/- mouse, which overexpresses human A53T-mutant α-syn and develops a lethal, reliably scored synucleinopathy when challenged with preformed α-syn fibrils injected into the brain ('brain-first' model) or into the peritoneum or gut wall ('body-first' models); survival, weight loss, and motor decline serve as disease measures. HET-s(218-298) is the prion domain of a fungal protein that forms highly stable, well-structured amyloid fibrils; because its atomic structure is known, selected surface residues can be substituted to display ('graft') specific conformational epitopes — surface patches defined by three-dimensional shape across stacked subunits — copied from the surface of α-syn fibrils. Flores-Fernandez et al. (2023 preprint; 2024 published) designed four such HET-s-derived candidates (α-SC3, α-SC6, α-SC8, α-SC9), each mimicking a different conformational epitope of α-syn fibrils, and showed in wild-type mice that each induces IgG antibodies recognizing pathological α-syn from diseased TgM83+/- mice and aggregates in DLB, MSA, and PD patient brain lysates, but not linear α-syn peptides; the candidates did not seed monomeric α-syn aggregation in RT-QuIC (a sensitive in-vitro amyloid amplification assay) or in cell models. That report left efficacy, safety, breadth, durability, and human translation open — and its named 'ongoing efficacy trials in TgM83 mice' have now reported: the quadrivalent vaccine prolonged median survival 8% (intracerebral challenge), 21% (intraperitoneal), and 22% (gut wall) (Pesch et al., 2024), and monovalent vaccination with individual candidates extended survival by up to 38% (intraperitoneal) and 42% (intragastric) while protecting weight and motor performance (Ma et al., 2026). The Ma et al. (2026) discussion itself delineates what remains unresolved: antibody titers were not measured at late post-challenge time points, so waning protection and the value of additional boosters are unknown; only prophylactic vaccination was tested, so therapeutic (post-onset) efficacy is undetermined; and the challenges used a single synthetic fibril preparation, although epitopes were designed from only two synthetic structures and patient-derived ex vivo structures exist. Antibodies from immunized mice bind monomeric α-syn in healthy brain to a lesser extent, and no dedicated assessment of autoimmune reactions or antibody-driven neuroinflammation in vaccinated animals has been reported. No clinical trial of this structure-based vaccine class is registered; registered α-syn vaccine trials (AFFITOPE, AC Immune's ACI-7104.056) all use other antigen formats.

Problem Statement

For HET-s(218-298)-scaffolded vaccines displaying conformational epitopes of α-synuclein amyloid fibrils — now proven prophylactically efficacious in fibril-challenged TgM83+/- mice — establish the preclinical and clinical profile required of a deployable synucleinopathy vaccine, jointly comprising: (1) in-vivo safety: whether the elicited antibodies provoke harmful autoimmune reactions, interfere with the physiological functions of native α-synuclein, or induce adverse neuroinflammation, assessed by dedicated histopathological and functional evaluation of vaccinated animals; (2) durability: how long antibody titers and protection persist after the immunization series (including post-challenge time courses) and whether booster dose, timing, route, and adjuvant can sustain protection; (3) breadth: whether protection extends beyond the single synthetic fibril strain used to date to diverse patient-derived α-synuclein strains and to vaccine candidates designed from ex vivo patient fibril structures; (4) therapeutic window: whether vaccination after peripheral α-synuclein fibrillization has begun (post-onset) still confers protection, or whether the approach is exclusively prophylactic; and (5) translation: whether the immunogenicity, specificity, safety, and efficacy observed in mice carry over to humans, to be settled by preclinical safety testing and registered clinical trials of this vaccine class. These five facets jointly determine the single overarching objective: whether structure-based conformational-epitope vaccination can become a clinically viable, disease-modifying intervention for Parkinson's disease and related synucleinopathies.

References

  1. Flores-Fernandez JM, Pesch V, Sriraman A, Chimal-Juarez E, Amidian S, Wang X, Duckering C, Fang A, Reithofer S, Ma L, Cortez LM, Sim VL, Tamgüney G, Wille H. Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson's disease and related disorders. Bioengineering & Translational Medicine 2024;9(4):e10665. doi:10.1002/btm2.10665, https://doi.org/10.1002/btm2.10665 (full text also at https://pmc.ncbi.nlm.nih.gov/articles/PMC11256163/)
  2. Flores-Fernandez JM, Pesch V, Sriraman A, Chimal-Juarez E, Amidian S, Wang X, Reithofer S, Ma L, Tamgüney G, Wille H. Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson's disease and related disorders. bioRxiv preprint, posted 2023-06-30. doi:10.1101/2023.06.30.547254, https://doi.org/10.1101/2023.06.30.547254
  3. Pesch V, Flores-Fernandez JM, Reithofer S, Ma L, Özdüzenciler P, Busch Y, Sriraman A, Wang Y, Amidian S, Kroepel CVM, Müller L, Lien Y, Rudtke O, Frieg B, Schröder GF, Wille H, Tamgüney G. Vaccination with structurally adapted fungal protein fibrils induces immunity to Parkinson's disease. Brain 2024;147(5):1644-1652. doi:10.1093/brain/awae061, https://doi.org/10.1093/brain/awae061 (full text also at https://pmc.ncbi.nlm.nih.gov/articles/PMC11068327/)
  4. Ma L, Reithofer S, Pesch V, Flores-Fernandez JM, Sriraman A, Duckering C, Amidian S, Özdüzenciler P, Müller L, Wille H, Tamgüney G. Vaccines mimicking conformational epitopes on α-synuclein fibrils provide immunity to Parkinson's disease. Brain 2026;149(8):2689-2701. doi:10.1093/brain/awag010, https://doi.org/10.1093/brain/awag010 (full text also at https://pmc.ncbi.nlm.nih.gov/articles/PMC13431816/)
  5. Kinoshita M, Kimura Y, Mochizuki H. Vaccination with structurally modified fungal protein fibrils: a new treatment for synucleinopathies? Brain 2024;147(5):1604-1606. doi:10.1093/brain/awae115, https://doi.org/10.1093/brain/awae115
  6. Fang A, Tang X, Fleming M, Tancowny B, Wang X, Wang Y, Daude N, Dorosh L, Fleck SC, Rathod V, Coustou V, Cervantes SA, Duque Velásquez C, Westaway D, Aiken J, McKenzie D, Telling G, Stepanova M, Saupe SJ, Siemer AB, Wille H. A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann-Sträussler-Scheinker disease mutation. Acta Neuropathologica 2026;151(1):41. doi:10.1007/s00401-026-03015-4, https://doi.org/10.1007/s00401-026-03015-4